Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
PureTech LYT, Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, LI, RUIXIANG, who is also the busiest examiner for the company. The prosecution is concentrated within 1 distinct art unit, which means all current activity is focused on a single technical group. The presence of 1 pending office action and 1 distinct examiner indicates that the company's current active portfolio is entirely under the review of LI, RUIXIANG.
With a busiest examiner pending count of 1, there is no diversification of examiner viewpoints or art unit standards in the current workload. Practitioners should focus their efforts on the specific practices of this 1 distinct examiner within the 1 distinct art unit. The success of the company's current prosecution efforts depends on the resolution of this 1 pending office action. This single action represents the total active engagement with the patent office at this time for the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253756 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | LI, RUIXIANG | 21d |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18253756 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | LI, RUIXIANG | 1674 | §103Other | Final Rejection | 21d | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPureTech LYT, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ruixiang Li has the most, with 1 of PureTech LYT, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
